Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The...

Prior research has demonstrated the potential of pharmacogenomics to improve drug therapy outcomes. However, translating these findings into routine clinical practice remains a challenge. It was already known that genetic variation influences drug response, but the integration of preemptive DNA sequencing into healthcare systems had not been widely tested. No prior work had resolved how to scale pharmacogenomic testing for large populations. This gap motivated the exploration of preemptive testing approaches. That uncertainty drove the need to assess the feasibility of implementing DNA sequencing in clinical workflows. The study aimed to address how to systematically apply genomic data to prescribing decisions. It was unclear whether preemptive approaches would be broadly applicable or limited to specific patient groups. The researchers sought to measure the frequency of actionable genetic variants across a large cohort.

The study aimed to implement preemptive DNA sequence-based pharmacogenomics testing in a large academic medical center. The specific problem addressed was the lack of scalable methods to integrate genomic data into routine prescribing. The motivation stemmed from the need to move beyond reactive testing models. The researchers wanted to assess how many patients would benefit from preemptive testing. They also aimed to develop tools and resources for clinical pharmacogenomics implementation. The study focused on measuring the frequency of clinically actionable genetic variants. It sought to compare DNA sequencing with genotyping for variant detection. The goal was to evaluate the feasibility of preemptive PGx testing in a real-world setting.

The study used targeted oligonucleotide-capture sequencing of 77 pharmacogenes. DNA was obtained from 10,077 consented volunteers in the Mayo Clinic Biobank. The sequencing method enabled detection of both common and rare genetic variants. Predicted drug response phenotypes for 13 genes were generated. These results were deposited preemptively into the electronic health record. The study focused on 21 drug-gene pairs with established clinical guidelines. The approach compared DNA sequencing to genotyping for variant identification. The researchers evaluated the number of actionable variants per patient.

The study found that 79% of participants had clinically actionable variants in three or more genes. DNA sequencing identified an average of 3.3 additional deleterious variants per patient. These variants would not have been detected using genotyping methods. The results showed that preemptive testing could be broadly applicable. The study demonstrated the feasibility of integrating genomic data into clinical workflows. The findings suggested that DNA sequencing provides more comprehensive variant detection. The approach revealed nearly universal patient applicability for PGx testing. The results supported the potential for more efficient healthcare resource use.

The study concluded that preemptive DNA sequencing can be implemented in clinical practice. The findings suggest that DNA sequencing provides broader variant detection than genotyping. The researchers propose that preemptive testing is broadly applicable to most patients. The study highlights the need for integrated institutional resources. The results support the potential for improved drug therapy through PGx testing. The authors suggest that DNA sequencing can identify more actionable variants. The study indicates that preemptive testing may lead to more efficient healthcare use. The findings imply that widespread implementation requires system-wide coordination.